City University of New York (CUNY)

CUNY Academic Works
Publications and Research

Brooklyn College

2020

3,7-Dihydroxytropolones Inhibit Initiation of Hepatitis B Virus
Minus-Strand DNA Synthesis
Ellen Bak
National Institutes of Health

Jennifer T. Miller
National Institutes of Health

Andrea Noronha
National Institutes of Health

John Tavis
St. Louis University

Emilio Gallicchio
CUNY Brooklyn College

See next page for additional authors

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/bc_pubs/321
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

Authors
Ellen Bak, Jennifer T. Miller, Andrea Noronha, John Tavis, Emilio Gallicchio, Ryan P. Murelli, and Stuart F. J.
Le Grice

This article is available at CUNY Academic Works: https://academicworks.cuny.edu/bc_pubs/321

molecules
Article

3,7-Dihydroxytropolones Inhibit Initiation of
Hepatitis B Virus Minus-Strand DNA Synthesis
Ellen Bak 1 , Jennifer T. Miller 1 , Andrea Noronha 1 , John Tavis 2 , Emilio Gallicchio 3,4,5 ,
Ryan P. Murelli 3,4,5 and Stuart F. J. Le Grice 1, *
1
2
3
4
5

*

Basic Research Laboratory National Cancer Institute, Frederick, MD 21702, USA; ellen.bak@nih.gov (E.B.);
millerj@mail.nih.gov (J.T.M.); andreanoronha1@gmail.com (A.N.)
Department of Molecular Microbiology and Immunology, St. Louis University, St. Louis, MO 63104, USA;
john.tavis@health.slu.edu
Department of Chemistry, Brooklyn College, The City University of New York, Brooklyn, NY 11210, USA;
EGallicchio@brooklyn.cuny.edu (E.G.); RPMurelli@brooklyn.cuny.edu (R.P.M.)
PhD Program in Chemistry, The Graduate Center of The City University of New York, New York,
NY 10016, USA
PhD Program in Biochemistry, The Graduate Center of The City University of New York, New York,
NY 10016, USA
Correspondence: legrices@mail.nih.gov

Academic Editor: Oriana Tabarrini
Received: 26 August 2020; Accepted: 19 September 2020; Published: 27 September 2020




Abstract: Initiation of protein-primed (-) strand DNA synthesis in hepatitis B virus (HBV) requires
interaction of the viral reverse transcriptase with epsilon (ε), a cis-acting regulatory signal located
at the 5’ terminus of pre-genomic RNA (pgRNA), and several host-encoded chaperone proteins.
Binding of the viral polymerase (P protein) to ε is necessary for pgRNA encapsidation and synthesis of
a short primer covalently attached to its terminal domain. Although we identified small molecules that
recognize HBV ε RNA, these failed to inhibit protein-primed DNA synthesis. However, since initiation
of HBV (-) strand DNA synthesis occurs within a complex of viral and host components (e.g., Hsp90,
DDX3 and APOBEC3G), we considered an alternative therapeutic strategy of allosteric inhibition
by disrupting the initiation complex or modifying its topology. To this end, we show here that
3,7-dihydroxytropolones (3,7-dHTs) can inhibit HBV protein-primed DNA synthesis. Since DNA
polymerase activity of a ribonuclease (RNase H)-deficient HBV reverse transcriptase that otherwise
retains DNA polymerase function is also abrogated, this eliminates direct involvement of RNase
(ribonuclease) H activity of HBV reverse transcriptase and supports the notion that the HBV initiation
complex might be therapeutically targeted. Modeling studies also provide a rationale for preferential
activity of 3,7-dHTs over structurally related α-hydroxytropolones (α-HTs).
Keywords: Hepatitis B virus; protein priming; epsilon RNA; minus strand DNA synthesis;
3,7-dihydroxytropolones

1. Introduction
Global estimates indicate that ~270 million individuals are chronically infected with hepatitis B
virus (HBV) [1], experiencing liver diseases such as cirrhosis and hepatocellular carcinoma which,
cumulatively, account for ~600,000 annual deaths [1,2]. HBV, a member of the Hepadnaviridae family,
is the smallest animal-infecting DNA virus, with a ~3.2 Kb genome comprising seven proteins encoded
by four overlapping genes [3,4]. HBV reverse transcriptase (P protein), the only enzyme of this genome,
comprises a terminal protein (TP) linked to the reverse transcriptase (RT)/ribonucleaseH (RNase H)
components by a spacer domain [5]. Following infection, partially double-stranded relaxed circular (rc)
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DNA is repaired in the nucleus, yielding covalently closed circular DNA (cccDNA), the transcriptional
template for host RNA polymerase II. Viral transcripts are transported to the cytoplasm and translated
into the core, pre-core protein, that is proteolytically processed and secreted as e-antigen, polymerase,
envelope, and X proteins. Single-stranded pre-genomic RNA (pgRNA) is then packaged into the
core during assembly of viral nucleocapsids and subsequently reverse-transcribed into minus-strand
DNA [3,6]. Due to its genome size and encoding of only a single enzyme, developing effective strategies
to treat HBV infections has been challenging [2]. Current options include immunomodulatory agents,
such as interferon-α and pegylated interferon-α, or oral nucleoside/nucleotide analogues such as
lamivudine, adefovir, telbivudine, entecavir, and tenofovir [7]. However, the potential side effects
following decades of drug exposure suggests a need for novel strategies, and possibly their incorporation
into combination therapies [8].
As with retroviral RTs, degradation of the RNA/DNA HBV replication intermediate is catalyzed by
its RT-associated RNase H domain. Although no inhibitor of HIV-1 RT RNase H function has advanced
to the clinic, intense efforts over almost 2 decades have made a plethora of compounds available for
testing its HBV counterpart [9,10]. Following reports that the natural product α-hydroxytropolone
(α-HT), β-thujaplicinol [11] inhibits HBV replication by sequestering the catalytic Mg++ in the
RNase H active site [12], modified α-HTs [13], 2-hydroxyisoquinoline-1,3(2H,4H)-diones [14] and
N-hydroxypyridinediones, have emerged as a new class of RNase H inhibitors [15]. The availability
of an active form of the isolated HBV RNase H domain [16] should also promote development of
high-throughput assays to accelerate drug-screening efforts.
Participation of several host factors is essential for early events of HBV minus-strand DNA
synthesis, an example of which is the Hsp90 complex [17,18]. It is therefore not unreasonable to
postulate that inducing dissociation of the multi-component initiation complex, or altering its topology,
might be exploited to abrogate HBV infection therapeutically [17]. With this in mind, we have adopted
the reconstituted in vitro HBV protein priming assay [19] to screen several classes of structurally diverse
small molecules for their ability to inhibit priming of HBV DNA synthesis. Surprisingly, two classes of
ligands that recognized the “priming loop” of HBV epsilon ε [6] failed to inhibit minus-strand DNA
synthesis. The α-HT β-thujaplicinol, previously shown to inhibit HBV RNase H activity, had likewise
little effect on initiation of DNA synthesis. In contrast, 3,7-dihydroxytropolones (3,7-dHTs), differing
from α-HTs in that they that bear an extra, contiguous oxygen atom on their heptatriene ring,
significantly reduced priming activity. Our findings that 3,7-dHTs inhibit protein priming by an
RNase H-deficient HBV RT that otherwise retains DNA polymerase function, suggests they target the
initiation complex in an RNase H-independent manner. Analyzing the composition of the priming
complex also indicates that it remains intact in the presence of 3,7-dHT 196. Our data therefore lends
support to a recent proposal of Jones et al., who have demonstrated that the triphosphate form of the
nucleoside analog Clevudine can inhibit priming of HBV minus-strand DNA synthesis via binding to
and distorting the DNA polymerase active site of P protein [20].
2. Results
2.1. Establishing the HBV Minus-Strand DNA Priming System
ε-Dependent initiation of HBV minus-strand DNA synthesis requires, in addition to the viral
polymerase, several eukaryotic chaperones [6,19]. Attempts to reconstitute the priming system from
purified components have been unsuccessful, leading Jones et al. to develop a recombinant mammalian
system using HEK293T cells transfected with plasmids expressing FLAG-tagged HBV polymerase
and ε RNA (Figure 1A, B, respectively) [19]. Figure 1C analyzes bead-bound proteins in the absence
and presence of the HBV P protein-expressing plasmid by sodium dodecyl sulfate/polyacrylamide gel
electrophoresis (SDS/PAGE). While we observed low-level non-specific binding in the mock transfection,
P protein and associated cellular chaperones could be visualized following transfection with the HBV
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Pol plasmid. Data of Figure 1D demonstrates that the reconstituted, immobilized priming complex
3 of 14
supported ε-dependent protein priming.
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initiation of DNA synthesis, while a mixture of dGTP and dATP (red) evaluates subsequent
elongation steps. (B) dGTP (upper) and dGTP/dATP-primed reactions (lower) in the presence of 3,7dHTs 196 and 272 and a control α-HT 111. (C) structures of 3,7-dHT 272 and α-HT 111. All analogs
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were tested at a final concentration of 100 μM.
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2.6. Activity of Non-Troponoid Nucleotidyltransferase Inhibitors
2.6. Activity of Non-Troponoid Nucleotidyltransferase Inhibitors
The N-naphthyridinone GSK364735, which shares a similar geometry and chelating function
with α-HTs, has been reported as a potent inhibitor of HIV-1 integrase by binding competitively to
the two-metal binding site of the integrase-HIV DNA complex [31,32]. Based on their mechanistic
similarity as enzymes of the nucleotidyltransferase superfamily, Tavis et al. subsequently showed that
both naphthyridinone- and N-hydroxypyridinedione-derived HIV-1 integrase inhibitors antagonized
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Tavis et al. also demonstrated efficacy of the diketo acid-derived integrase inhibitors Raltegravir
Tavis et al. also demonstrated efficacy of the diketo acid-derived integrase inhibitors Raltegravir
and Elvitegravir as HBV RNase H inhibitors [30]. These and Dolutegravir were therefore examined in
and Elvitegravir as HBV RNase H inhibitors [30]. These and Dolutegravir
were therefore examined
the HBV priming assay. Figure 7B examines [32 P]dGTP-primed
and [32 P]dATP-primed reactions in the
in the HBV priming assay. Figure 7B examines [32P]dGTP-primed and [32P]dATP-primed reactions in
presence of Raltegravir, Elvitegravir, and Dolutegravir, comparing this with the 3,7-dHT 196. Of these
the presence of Raltegravir, Elvitegravir, and Dolutegravir, comparing this with the 3,7-dHT 196. Of
integrase inhibitors, Elvitegravir invoked a slight diminution of priming activity in the presence of
these integrase inhibitors,
Elvitegravir invoked a slight diminution of priming activity in the presence
either [32 P]dGTP
or [32 P]dATP, while Raltegravir and Dolutegravir were essentially inactive.
of either [32P]dGTP or [32P]dATP, while Raltegravir and Dolutegravir were essentially inactive.
2.7. 3,7-dHT 196 Does Not Induce Dissociation of the HBV Initiation Complex
2.7. 3,7-dHT 196 Does not Induce Dissociation of the HBV Initiation Complex
The multi-protein nature of the HBV initiation complex [19] raised the possibility that inhibition of
The multi-protein nature of the HBV initiation complex [19] raised the possibility that inhibition
priming by 3,7-dHTs might reflect (a) disruption and release of one or more of the protein constituents,
of priming by 3,7-dHTs might reflect (a) disruption and release of one or more of the protein
or (b) dissociation of the multi-protein complex from HBV ε RNA. To investigate this experimentally,
constituents, or (b) dissociation of the multi-protein complex from HBV ε RNA. To investigate this
we examined the nucleic acid and protein components of the immobilized initiation complex in
experimentally, we examined the nucleic acid and protein components of the immobilized initiation
the absence and presence of 3,7-dHT 196. In Supplementary Figure S1A, ε RNA was visualized
complex in the absence and presence of 3,7-dHT 196. In Supplementary Figure S1A, ε RNA was
following denaturing PAGE by SYBR Gold staining, or indirectly by reverse transcription with
visualized following denaturing PAGE by SYBR Gold staining, or indirectly by reverse transcription
a Cy5 end-labeled primer (Supplementary Figure S1B). In both instances, ε RNA was detected
with a Cy5 end-labeled primer (Supplementary Figure S1B). In both instances, ε RNA was detected
following incubation with 3,7-dHT 192, confirming that it was neither degraded nor displaced from
following incubation with 3,7-dHT 192, confirming that it was neither degraded nor displaced from
the initiation complex. Alternatively, following release of the bead-immobilized initiation complex,
its constituents were analyzed by SDS/PAGE and silver staining. This analysis is illustrated in
(Supplementary Figure S1C), where relevant proteins of the complex have been assigned according
to Jones et al. [19]. While qualitative, silver staining shows minimal difference in eluates of extracts
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3.3.Discussion
Discussion
Among the many steps in the HBV life cycle that might be considered therapeutically accessible,
nucleoside and nucleotide analogs presently play a prominent role by antagonizing activity of the
viral polymerase, evidenced by approval of the drugs lamivudine (3TC), adefovir dipivoxil (ADV),
tenofovir (TDF) [34], entecavir (ETV), and telbivudine (LdT) [35]. Mechanistically, these chemotypes
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act as chain terminators through their inability to be extended following incorporation into nascent
DNA. As a complement to chain termination, and with combination therapy in mind, inhibition of
HBV P protein-associated RNase H is gaining increasing attention, evidenced by promising results
with α-HTs and hydroxyimide chemotypes [9]. However, the multi-component nature of the HBV
minus-DNA initiation complex, requiring a combination of viral and host proteins [17,18] and a unique
conformation dissimilar to that catalyzing subsequent DNA strand elongation, raises alternatives to
direct active site inhibition, such as (a) allosteric inhibition by sequestering the initiation complex to
alter its overall topology or induce dissociation of a critical component [36], or (b) non-competitive
inhibition, an example of which is foscarnet, which occupies the pyrophosphate-binding site on the viral
enzyme [37]. Another encouraging example of noncompetitive inhibition has been proposed by Jones
et al. [20], who demonstrated that Clevudine triphosphate (a derivative of thymidine triphosphate)
inhibits HBV minus-strand DNA priming by distorting the active site of viral P protein in a manner
incompatible with polymerization, which would be analogous to nonnucleoside RT inhibitors (NNRTI)
of HIV RT [38]. With these issues in mind, we elected to establish the in vitro HBV priming system of
Figure 1 to evaluate several chemotypes that have arisen from our HTS efforts to identify small-molecule
protein and RNA-binding antagonists.
Based on the requirement for divalent metal (Mg++ ) at the DNA polymerase and RNase H active
sites of HBV P protein, α–HTs, which we [11], and others [9,13,15,25,26,39] have studied extensively as
viral RNase H inhibitors, were a logical starting choice. However, despite showing good activity against
recombinant HBV RNase H, α–HTs were poorly active in inhibiting minus-strand priming. In contrast,
we have demonstrated here that (a) structurally related 3,7-dHTs (compounds 196, 272, and 362) inhibit
priming and (b) the most promising, compound 196, inhibits priming activity of an RNase H-deficient,
polymerase-proficient HBV P protein. The requirement for an additional -OH group at position 3
of the tropolone ring is also suggested by lack of priming activity of compound 335, which replaces
this with -Br. A second class of non-tropolone HBV RNase H inhibitors, N-hydroxypyridinediones,
also fails to inhibit priming, illustrating that the effect demonstrated here is specific to 3,7-dHTs.
Since analysis of the RNA and protein components of the initiation complex suggest it remains intact
(Supplementary Figure S1), we conclude that the 3,7-dHTs analyzed in this communication likely act
through sequestration of divalent metal at the DNA polymerase active site. Indeed, this postulate is
not without precedent, since Didierjean et al. have reported that although they antagonize RNase H
activity of HIV-1 RT, 3,7-dHTs [28] are more specific for DNA polymerase function.
According to the 2-metal-ion catalysis mechanism proposed by Steitz and Steitz [40], the catalytic
Mg++ ions at the RNase H active site of HIV-1 RT are separated by ~4Å, which Didierjean et al. have
proposed is unfavorable for the interaction with tropolones [28]. However, in the complex of HIV-1
RT containing duplex DNA and the incoming dNTP [41], the two Mg++ ions in the DNA polymerase
active site are separated by 3.57Å, which would be more in line with the 3.7Å separation distance
of the two ions coordinated by 3,7-dHTs. Based on inhibition and modeling studies with inositol
monophosphatase, Piettre et al. have proposed that three of the four contiguous oxygen atoms of
3,7-dHTs permit tridentate engagement with Mg++ ions, while the fourth oxygen atom is able to
engage favorably with a main chain carbonyl group within the active site [42]. The fourth oxygen of
the tropolone ring may similarly establish favorable contacts in the polymerase active site of HBV P
protein, which modeling suggests could be Arg389 . While detailed structural analysis will be necessary
to validate these hypotheses, the finding of two chemotypes (Clevudine and 3,7-dHTs) that target the
critical first step in HBV minus-strand DNA synthesis should spur new efforts to identify a novel class
of therapeutic agents to target the HBV initiation complex. Since all studies reported here are based on
an in vitro priming assay, future efforts should focus on determining how the activity of 3,7-dHTs we
have identified translate into inhibition of HBV replication in infected cells.
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4. Materials and Methods
4.1. α–HTs and 3,7-dHTs
Compounds 196, 272, and 362 were reported Hirsch et al. [39] (as compounds 6a, 6c, and 6e,
respectively), 111, 113, 146, and 335, by Lomonosova et al. [26], compounds 231, 232, 233, 234,
and 235 by Berkowitz et al. [43], and compound 055G by D’Erasmo et al. [44] (as compound 4n).
N-hydroxypyridinediones 514 and 667 have been reported by Tavis et al. [30].
4.2. Plasmids
Recombinant plasmids expressing 3× FLAG-tagged, full-length HBV DNA polymerase
(pCMV-3FHP) and Hε RNA (pCMV-HE), derived from the 50 end of HBV pgRNA, were a generous gift
from Dr. Jianming Hu, Penn State University, College of Medicine, State College, PA, USA, and whose
construction is described in Jones et al. [19]. Plasmid for expressing RNase H-deficient HBV polymerase
(Asp702 Ala/Glu731 Ala) was prepared using a QuikChange Multi Site-Directed Mutagenesis kit (Agilent,
Santa Clara, CA, USA) using the following primers:
Forward primer 50 -CCAAGTGTTTGCTGCCGCAACCCCCACTG-30 ,
Reverse primer 50 -CGATCCATACTGCGGCACTCCTAGCCGCTTG-30 ,
RNase H-inactivating mutations [30] were verified by DNA sequencing.
4.3. Protein, RNA Expression and Purification
HEK293T cells were transfected with pCMV-3FHP only (HBV polymerase, or P), or in combination
with pCMV-Hε (RNA) using the Lipofectamine procedure (Invitrogen, Carlsbad, CA, USA). Two days
post- transfection, cells were harvested as described in Reference [5]. P and P/ε complexes (PE) were
purified with M2 anti-FLAG antibody (Millipore-Sigma, St. Louis, MO, USA) pre-bound to Protein A/G
magnetic beads (ThermoFisher Scientific, Waltham, MA, USA), using 50 µL of FLAG beads per T75
flask (75 cm2 ) lysate (seeding with approximately 4.0 × 106 cells 24 h prior to transfection). Beads were
aliquoted into single-use portions and stored at −80 ◦ C.
4.4. In Vitro Protein Priming
5 µL of P or Pε M2 beads/reaction were resuspended in priming buffer (20 mM Tris-HCl pH
7.0, 15 mM NaCl, 10 mM KCl, 4 mM MgCl2 ) with 1× (ethylenediaminetetraacetate) EDTA-free
protease inhibitor cocktail (Millipore-Sigma), 2 mM dithiothreitol DTT), 1 mM phenylmethylsulfonyl
fluoride (PMSF), and 1 U RNasin RNase inhibitor/µL buffer. Following 10-min pre-incubation with
analogs and shaking at 25 ◦ C, 0.5 µL of [α-32 P]dGTP (10 mCi/mL (3000 Ci/mmol); PerkinElmer,
Waltham, MA, USA) was added for a total volume of 20 µL/reaction, and mixtures were incubated
at 25 ◦ C for 1 h with shaking. Beads were washed twice in 300 mM NaCl, 0.05% Tween in 0.05 M
Tris/HCl, Ph 7.6, 0.15 M NaCl (TBST), then incubated at 95 ◦ C in 2× SDS sample buffer (Invitrogen)
for 2 min. The supernatant was separated from beads using a magnetic rack and fractionated at
room temperature through a 4–12% Bis-Tris polyacrylamide gel (200 V) in 1× MES running buffer
(Invitrogen). To detect nucleotide incorporation at elongation and strand transfer, 0.5 µL of either
[α-32 P]dATP (10 mCi/mL (3000 Ci/mmol); PerkinElmer) was mixed with 6.5 nM unlabeled dGTP,
or [α-32 P] thymidine triphosphate (TTP) (10 mCi/mL (3000 Ci/mmol); PerkinElmer) was mixed with
6.5 nM unlabeled dGTP and 30 nM unlabeled dATP. Phosphorimaging was used to detect [32 P]-labeled
HP as the product of in vitro protein priming. Scanning was performed with a Typhoon FLA 9500
(GE Healthcare, Chicago, IL, USA) and quantitation used ImageQuant TL software (GE Healthcare).
4.5. In Vitro Binding of ε RNA to HBV Polymerase
M2 beads containing immobilized HBV P protein were resuspended in binding buffer (50 mM
Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.05% NP-40) with 1× complete with EDTA protease
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inhibitor cocktail (Millipore-Sigma), 1 mM PMSF, 2 mM dithiothreitol (DTT), and 1 U RNasin RNase
inhibitor (Promega, Madison, WI, USA)/µL, and incubated with ligands for 10 min at 25 ◦ C with
shaking, followed by incubation with 1 M Cy5-labeled HBV ε RNA (137 nt) for 90 min at 25 ◦ C in the
dark with shaking. Beads were washed 4 times in TBST, then resuspended in 10 µL of 2× loading
buffer (Invitrogen) and incubated at 90 ◦ C for 3 min. Supernatant from the beads was fractionated
through a 4–12% Bis-Tris gel in 1× MES running buffer as described above. Cy5-labeled ε RNA was
detected and quantified as described above.
4.6. HBV ε RNA Detection
M2 beads containing HBV P protein bound to ε RNA were resuspended in priming buffer (5 µL
of beads/reaction) and incubated with either DMSO (control) or 3,7-dHT 196 for 10 min at 25 ◦ C,
with shaking. Samples were next resuspended in 50 mM Tris/HCl, pH 8.0, 75 mM KCl and annealed
at 85 ◦ C with 2.5 pmole of Cy5-labeled HPε primer (50 Cy5/CGAGAGTAACTCCACAGTAGCTCC
30 ). After separating reaction supernatants from magnetic beads, a master mix was added to the
supernatant for a final concentration of 0.5 mM deoxynucleoside triphosphates dNTPs), 3 mM MgCl2 ,
4 mM DTT. Urea gel loading buffer (1× Tris/Borate/EDTA containing 7 M Urea) was added to the
T0 reactions prior to adding 50 U/µL SuperScript Reverse Transcriptase (ThermoFisher Scientific).
For other time points, after addition of RT, samples were incubated at 45 ◦ C for 10 min, denatured
in 7 M urea loading buffer at 95 ◦ C for 3 min, then placed on ice. Samples were resolved on a 6%
polyacrylamide (19:1 acryl:bis)/7 M urea gel in 1× TBE. Cy5-labeled, reverse transcribed primer was
detected as described above.
4.7. Modeling Ligand Binding within the HBV Polymerase Active Site
Molecular docking of compounds 111, 196, 272, 335, and 362 utilized the homology model
structure of HBV bound to deoxycytidine triphosphate (dCTP) and a double-stranded DNA template
primer proposed by Das et al. [33] as the receptor. The receptor was prepared using the Protein
Preparation Wizard of the Maestro molecular modeling environment version 2019-4 (Schrödinger,
Inc., New York, NY, USA). Residue G22 of chain F of the primer DNA strand was deleted to provide
space for the incoming ligand and to mimic inhibition of elongation. The compounds were prepared
using the LigPrep facility at neutral pH and default settings. The docking grid and subsequent ligand
docking calculation were performed using the Glide program using Standard Precision and default
settings, placing the center of the docking box at the location of the reference-bound dCTP. The binding
pose with the lowest energy was retained for analysis.
5. Conclusions
Small molecules that recognize the “priming loop” of HBV ε RNA are unlikely to inhibit
minus-strand DNA synthesis by inducing dissociation of the high-affinity, multi-protein initiation
complex. In contrast, here, we showed that 3,7-dHTs, in contrast to the structurally related α–HTs,
inhibit HBV P protein-primed initiation of minus-strand DNA, and provide a rationale for this by
modeling the former into the P protein DNA polymerase active site. Combined with ongoing studies,
this observation opens the notion of developing ligands that independently target the DNA polymerase
and RNase H active sites of HBV P protein.
Supplementary Materials: Figure S1: 3,7-dHT 196 does not comprise the integrity of the HBV priming complex.
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